Cannabidiol preserves astrocyte viability and attenuates injury-induced glial stress responses across zebra finch song control nuclei.

Marshall D.; Litwa K.; Soderstrom K. · Frontiers in pharmacology · 2026

**Background & Methods** This review study examined cannabidiol's (CBD) neuroprotective mechanisms in a zebra finch microlesion model simulating traumatic brain injury (TBI) recovery. Researchers administered systemic CBD to investigate whether astrocyte preservation contributes to previously observed benefits in vocal recovery, inflammatory reduction, and synaptic protection following targeted damage to the premotor nucleus HVC. **Key Findings** • CBD preserved astrocyte viability and attenuated injury-induced lysosomal stress responses across interconnected song-control nuclei (HVC, RA, Area X), suggesting astrocytes as a critical cellular target for neuroprotection. • CBD suppressed reactive astrocyte markers (C3, S100A10, aromatase) while upregulating metabolic and antioxidant transcripts including glutamine synthetase and GCLM, indicating modulation of glial activation toward a protective phenotype. • CBD treatment reduced neuronal apoptosis in the lesioned HVC region, supporting a mechanism whereby astrocyte-mediated support limits secondary neuronal death following TBI. **Dosage & Administration** Cannabidiol 10 mg/kg/day administered intramuscularly (IM) for 7 days. **Safety & Adverse Effects** The abstract describes CBD as possessing "a favorable safety profile" and notes it is non-euphorigenic, distinguishing it from psychoactive cannabinoids. No specific adverse effects were reported in this study. Existing anti-inflammatory therapies were noted to be limited by systemic side effects with chronic use, suggesting CBD's improved tolerability profile. **Evidence Quality** As a review article examining findings from a songbird model, this study provides moderate evidence with notable limitations. The zebra finch microlesion model, while useful for investigating circuit-level neuroprotection and vocal learning recovery, has uncertain translational validity to human TBI pathophysiology. Findings are limited to a single animal model and do not include human clinical trials. The 7-day treatment window may not reflect chronic TBI scenarios or long-term CBD efficacy. However, the mechanistic focus on astrocyte-mediated protection addresses a previously under-characterized pathway and provides a testable hypothesis for mammalian TBI models. The study supports CBD as a promising candidate for translational research but cannot establish clinical recommendations without human evidence.

More recent cannabis research